



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Neil S. Cutshall and Kraig M. Yager
Application No. : 10/781,340
Filed : February 17, 2004
For : Pharmaceutical Uses and Synthesis of Nicotinamide-N-Oxides

Examiner : Rita J. Desai
Art Unit : 1625
Docket No. : 60117-106
Date : June 21, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO/SB/08. Copies of the references are enclosed. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application. No fee is due at this time in accordance with 37 C.F.R. § 1.97(b).

Respectfully submitted,
Neil S. Cutshall
DAVIS WRIGHT TREMAINE LLP

By 
Jane E. R. Potter
Registration No. 33,332

Enclosure:
Postcard
Form PTO/SB/08
Cited References (20)

1201 Third Avenue, 2200
Seattle, WA 98101-3045
Phone: (206) 622-3150
Facsimile: (206) 757-7700



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/781,340
Filing Date	February 17, 2004
First Named Inventor	Neil S. Cutshall
Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	60117-106

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOISVERT, W. A. et al., <i>Am J Pathology</i> 168(4):1385-1395, 2006.	
		BUSCH-PETERSEN, J., <i>Current Topics in Medicinal Chemistry</i> 6:1345-1352, 2006.	
		CATAISSON, C. et al., <i>J Clinical Investigation</i> 116(110):2757-2766, 2006.	
		DONNELLY, L. and BARNES, P., <i>TRENDS in Pharmacological Sciences</i> 27(10):546-553, 2006.	
		FARKAS, L. et al., <i>Chest</i> 128:3724-3734, 2005.	
		GARAU, A. et al., <i>Eur. Cytokine Netw.</i> 17(1):35-41, 2006.	
		GORDON, J. R. et al., <i>J Leukocyte Biology</i> 78:1-8, 2005.	
		LIAO, L. et al., <i>Pediatric Research</i> 60(3):299-303, 2006.	
		LONDHE, V. A. et al., <i>Pediatric Research</i> 58(5):919-926, 2005.	
		MATHESON, M. C., <i>J Hum Genet</i> 51:196-203, 2006.	
		NICHOLSON, G. C., <i>Pulmonary Pharmacology & Therapeutics</i> 20:52-59, 2007.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/781,340
Filing Date	February 17, 2004
First Named Inventor	Neil S. Cutshall
Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	60117-106

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PANINA, P. et al., <i>Current Drug Targets</i> 7:669-674, 2006.	
		PAPI, A. et al., <i>Pro Am Thorac Soc</i> 3:245-251, 2006.	
		QIU, Y. et al., <i>Thorax Online First</i> , March 21, 2007 as 10.1136/thx.2006.066670.	
		REUTERSHAN, J., <i>Drug News Perspect</i> 19(10):615-623, 2006.	
		RIOS-SANTOS, F. et al., <i>Am J Respir Crit Care Med</i> 175:490-497, 2007.	
		STEFANOVIC, L. AND STEFANOVIC, B., <i>J Interferon & Cytokine Res</i> 26:760-770, 2006.	
		WEATHINGTON, N. et al., <i>Nature Medicine</i> 12(3):317-323, 2006.	
		WISLEZ, M. et al., <i>Cancer Res</i> 66(8):4198-4207, 2006.	
		PHARMACOPEIA, Press Release, May 13, 2006, Princeton, NJ.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.